Published in Therap Adv Gastroenterol on March 01, 2016
Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place. Intest Res (2016) 0.82
Irritable Inflammatory Bowel Syndrome as a Distinct Disease Entity. J Neurogastroenterol Motil (2016) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology (2007) 5.04
Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol (2010) 4.45
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 3.89
Peripheral mechanisms in irritable bowel syndrome. N Engl J Med (2012) 3.40
Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One (2015) 3.37
Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology (2010) 3.32
Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol (2002) 2.85
Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology (2011) 2.79
Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut (2012) 2.60
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology (2011) 2.60
Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther (2012) 2.51
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut (2011) 2.49
Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil (2012) 2.49
Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2012) 2.46
Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut (1983) 2.39
A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol (2015) 2.35
Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther (2013) 2.28
Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol (2010) 2.23
Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol (2014) 2.11
Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess (2013) 2.06
Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand J Gastroenterol (2014) 2.05
Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut (2013) 1.98
Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol (2011) 1.89
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil (2012) 1.87
Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol (2014) 1.82
Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut (2013) 1.82
Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol (2009) 1.76
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2012) 1.73
Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis (2008) 1.65
Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. Gastroenterology (2008) 1.64
Gut/brain axis and the microbiota. J Clin Invest (2015) 1.64
Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol (2014) 1.63
Randomised controlled trial of mesalazine in IBS. Gut (2014) 1.58
IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci (2004) 1.53
Genomic and clinical effects associated with a relaxation response mind-body intervention in patients with irritable bowel syndrome and inflammatory bowel disease. PLoS One (2015) 1.52
Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther (2012) 1.48
Epidemiology of IBS. Gastroenterol Clin North Am (2011) 1.42
Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol (2013) 1.41
Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol (2010) 1.41
A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci (2009) 1.39
Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol (2000) 1.32
A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol (2014) 1.30
Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol (2000) 1.29
Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology (2014) 1.22
Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol (1999) 1.22
Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol (2013) 1.21
A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol (2012) 1.21
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2013) 1.20
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2012) 1.19
Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohns Colitis (2008) 1.18
Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog (2010) 1.17
The immune system in irritable bowel syndrome. J Neurogastroenterol Motil (2011) 1.16
Inflammatory bowel disease and irritable bowel syndrome: similarities and differences. Curr Opin Gastroenterol (2014) 1.16
Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol (2012) 1.16
Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. World J Gastroenterol (2012) 1.16
Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil (2011) 1.14
Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther (2014) 1.14
Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol (2015) 1.13
The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol (2009) 1.13
Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology (2014) 1.12
Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol (2008) 1.11
The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.11
The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam (2012) 1.09
Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol (2011) 1.09
Diagnostic power of fecal calprotectin in inflammatory and functional intestinal disorders. Scand J Gastroenterol (2015) 1.07
Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol (2011) 1.07
Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol (2011) 1.06
Genetics of the innate immune response in inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.05
Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil (2014) 1.03
Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver (2015) 1.03
Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol (2014) 1.03
Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors. Brain Behav Immun (2009) 1.02
Treatment of IBD: where we are and where we are going. Am J Gastroenterol (2014) 1.02
The microbial basis of inflammatory bowel diseases. J Clin Invest (2014) 1.01
CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-α. PLoS One (2012) 1.01
Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology (2015) 1.01
Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther (2015) 1.01
The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol (2006) 1.00
Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut (2010) 0.98
Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol (2012) 0.97
Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep (2015) 0.96
The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes (2014) 0.96
Irritable bowel syndrome, inflammatory bowel disease and the microbiome. Curr Opin Endocrinol Diabetes Obes (2014) 0.95
Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission. Gastroenterol Res Pract (2013) 0.94
Review article: monitoring the activity of Crohn's disease. Aliment Pharmacol Ther (2002) 0.94
Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci (2014) 0.92
Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes. Int J Med Microbiol (2014) 0.92
The overlap between IBS and IBD: what is it and what does it mean? Expert Rev Gastroenterol Hepatol (2014) 0.91
The microbiota link to irritable bowel syndrome: an emerging story. Gut Microbes (2012) 0.91
Treatment of irritable bowel syndrome in outpatients with inflammatory bowel disease using a food and beverage intolerance, food and beverage avoidance diet. Inflamm Bowel Dis (2007) 0.90
Rectal mucosal nitric oxide in differentiation of inflammatory bowel disease and irritable bowel syndrome. Clin Gastroenterol Hepatol (2005) 0.90
Cytokines and irritable bowel syndrome: where do we stand? Cytokine (2011) 0.89
Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. Eur J Gastroenterol Hepatol (2011) 0.88
Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndrome. PLoS One (2014) 0.88
Narcotic use for inflammatory bowel disease and risk factors during hospitalization. Inflamm Bowel Dis (2011) 0.88
Prodromal irritable bowel syndrome may be responsible for delays in diagnosis in patients presenting with unrecognized Crohn's disease and celiac disease, but not ulcerative colitis. Dig Dis Sci (2011) 0.88
Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther (2014) 0.88
Immunological Biomarkers in Postinfectious Irritable Bowel Syndrome. J Travel Med (2015) 0.87
Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motil (2013) 0.87